MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$10,090K
EPS
-$0.29
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
6,743 9,468* 7,000 3,200
General and administrative
3,808 2,756* 3,040 4,016
Total operating expenses
10,551 12,224 10,040 7,216
Loss from operations
-10,551 -12,224* -10,040 -7,216
Interest income
523 773* 687 754
Other income
-0* --
Net loss attributable to common stockholders
-10,028 -11,451* -9,353 -6,462
Unrealized (loss) gain on investments
-62 2* 39 -23
Comprehensive loss
-10,090 -11,449 -9,314 -6,485
Basic EPS
-0.29 -0.379 -0.31 -0.21
Diluted EPS
-0.29 -0.379 -0.31 -0.21
Basic Average Shares
34,059,876 30,198,683 30,276,230 30,172,328
Diluted Average Shares
34,059,876 30,198,683 30,276,230 30,172,328
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$10,090K Net lossattributable to common...-$10,028K Unrealized (loss) gain oninvestments-$62K Interest income$523K Loss from operations-$10,551K Total operatingexpenses$10,551K Research and development$6,743K General andadministrative$3,808K

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics, Inc. (ANTX)